Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Aug 29;19(1):855.
doi: 10.1186/s12885-019-6080-8.

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma

Lina Benaniba  1 , Benoit Tessoulin  1 , Sabrina Trudel  1 , Catherine Pellat-Deceunynck  2   3 , Martine Amiot  1   2   3 , Stéphane Minvielle  1   2   3 , Pierre Antoine Gourraud  4 , Sophie de Visme  4 , Hervé Maisonneuve  5 , Anne Lok  1 , Steven Le Gouill  1   2 , Philippe Moreau  1   2   3 , Cyrille Touzeau  6   7   8
Affiliations
Observational Study

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma

Lina Benaniba et al. BMC Cancer. .

Abstract

Background: Despite recent advances in the treatment of multiple myeloma, the disease constantly relapses and is still considered as incurable. The current knowledge about the biological mechanisms underlying resistance to the different class of drugs in multiple myeloma remains poor. The primary objective of the MYRACLE (Myeloma Resistance And Clonal Evolution) cohort, a multicenter prospective cohort of patients with multiple myeloma, is to address this limitation. We here describe the study background, design and methods used for this cohort.

Methods/design: All patients (> 18 year old) diagnosed with de novo or relapsed multiple myeloma and treated in two hematology department from west of France are included in the MYRACLE cohort. Patients provide a signed informed to be included in the study. All subjects are followed until refusal to participate in the study or death. The MYRACLE cohort prospectively collects data on socio-economic status, medical status, imaging, prognosis factors, MM therapies and associated events (resistance, safety issues). Patients also complete standardized quality of life questionnaires. In addition, bone marrow samples will be collected at time of diagnosis and relapses to perform biomarkers analysis and functional assays exploring mechanisms underlying drug resistance.

Discussion: The "real-life" MYRACLE cohort offers the opportunity to prospectively collect epidemiological, medical, QoL and biological data from MM patients during the course of the disease (at time of diagnosis and subsequent relapses). At mid-tem, this integrative cohort will be unique at producing a large variety of data that can be used to conceive the most effective personalized therapy for MM patients. Additionally, the MYRACLE cohort will allow integrating the medical care of MM patients in a health and pharmacoeconomic perspective.

Keywords: Apoptosis; Cohort; Drug resistance; Epidemiology; Multiple myeloma; P53; Pharmacoeconomy; Quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors declare to have no competing interest.

Figures

Fig. 1
Fig. 1
Study visits (a) and summary of collected data (b) throughout the MYRACLE cohort study. Legend: BM, bone marrow ISS, international scoring system
See this image and copyright information in PMC

References

    1. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(suppl_4):iv52–iv61. doi: 10.1093/annonc/mdx096. - DOI - PubMed
    1. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:2863–2869. doi: 10.1200/JCO.2015.61.2267. - DOI - PMC - PubMed
    1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520. doi: 10.1182/blood-2007-10-116129. - DOI - PMC - PubMed
    1. Moreau Philippe, Touzeau Cyrille. Multiple Myeloma: From Front-Line to Relapsed Therapies. American Society of Clinical Oncology Educational Book. 2015;35:e504–e511. doi: 10.14694/EdBook_AM.2015.35.e504. - DOI - PubMed
    1. Touzeau C, Moreau P, Dumontet C. Monoclonal antibody therapy in multiple myeloma. Leukemia. 2017;31:1039–1047. doi: 10.1038/leu.2017.60. - DOI - PubMed

Publication types